The double marker GFAP+/SVN+ subpopulation of CD9+ exosomes was much higher in glioma patients (range 0.6 – 27.2%; mean = 6.8%) than in controls (range 0.0 – 0.1; mean = 0.03%), a 227-fold difference (Table 2). This evidence concerns the gene CD9 and central nervous system cancer.